Lung cancer is the leading cause of death worldwide. The incidence of lung Cancer is rising alarmingly in India owing to an increase in smoking and air pollution. Non-small cell lung cancer (NSCLC) constitutes a large percentage of all lung cancers and is known to metastasize rapidly. Ramucirumab is a recombinant monoclonal antibody which was first approved for gastric/gastroesophageal carcinoma and is now also used as a second line therapy in NSCLC. Ramucirumab stops angiogenesis by blocking the vascular endothelial growth factor (VEGF 2) pathway, thus disrupting the primary mechanism of cancer metastasis.
Several clinical trials attested the safety and efficacy of Ramucirumab as second-line therapy in advanced NSCLC patients. Eli Lilly and Docplexus have organized an interactive Webinar on 9 th February 2019 at 3:00 pm . In this webinar session, Dr. Rolf A. Stahel will talk…
